Quantcast

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

SUMMIT, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/MS?src=hash" target="_blank"gt;#MSlt;/agt;–Celgene Corporation (NASDAQ:CELG) today announced that the Company has
submitted a New Drug Application to the U.S. Food and Drug
Administration (FDA) for ozanimod for the treatment of adults with
relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral,
sphingosine 1-phosphate (S1P) receptor modulator, which binds with high
affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

The pivotal efficacy and safety data provided in the application result
from the SUNBEAM and RADIANCE Part B phase 3,
multicenter, randomized, double-blind, double-dummy, active-controlled
trials.

“New oral treatment options with differentiated profiles like ozanimod
are needed to help address an unmet need for people with relapsing forms
of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene.
“With concurrent applications in the U.S. and EU, we look forward to
advancing this promising medicine through the regulatory review process
to provide a new option for the treatment of RMS in 2020.”

Earlier this month, the Company also submitted a Marketing Authorization
Application to the European Medicines Agency for adults with
relapsing-remitting multiple sclerosis.

Ozanimod is an investigational compound that is not approved for any use
in any country.

About SUNBEAM™

SUNBEAM is a pivotal, phase 3, multicenter, randomized, double-blind,
double-dummy, active-controlled trial evaluating the efficacy, safety
and tolerability of two doses of oral ozanimod (0.92 mg and 0.46 mg,
equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) against weekly
intramuscular interferon beta-1a (Avonex®) for at least a
12-month treatment period. The study included 1,346 people living with
RMS across 152 sites in 20 countries.

The primary endpoint of the trial was annualized relapse rates (ARR)
during the treatment period. The secondary MRI endpoints included the
number of new or enlarging hyperintense T2-weighted brain MRI lesions
over 12 months, number of gadolinium-enhanced brain MRI lesions at month
12 and percent change from baseline in whole brain volume at month 12.
Cortical grey and thalamic volume changes were also prospectively
assessed versus active comparator.

An analysis of the time to onset of 3-month confirmed disability
progression was pre-specified using pooled data from both the SUNBEAM
and RADIANCE Part B phase 3 trials.

About RADIANCE™

RADIANCE Part B is a pivotal, phase 3, multicenter, randomized,
double-blind, double-dummy, active-controlled trial evaluating the
efficacy, safety and tolerability of two doses of oral ozanimod (0.92 mg
and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively)
against weekly intramuscular interferon beta-1a (Avonex®)
over a 24-month treatment period. The study included 1,320 people living
with RMS across 150 sites in 21 countries.

The primary endpoint of the trial was ARR over 24 months. The secondary
MRI endpoints included the number of new or enlarging hyperintense
T2-weighted brain MRI lesions over 24 months, number of
gadolinium-enhanced brain MRI lesions at month 24 and percent change
from baseline in whole brain volume at month 24. Cortical grey and
thalamic volume changes were also prospectively assessed versus active
comparator.

An analysis of the time to onset of 3-month confirmed disability
progression was pre-specified using pooled data from both the SUNBEAM
and RADIANCE Part B phase 3 trials.

About Ozanimod

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator,
which binds with high affinity selectively to S1P subtypes 1 (S1P1)
and 5 (S1P5). Ozanimod causes lymphocyte retention in
lymphoid tissues. The mechanism by which ozanimod exerts therapeutic
effects in multiple sclerosis is unknown, but may involve the reduction
of lymphocyte migration into the central nervous system.

Ozanimod is in development for immune-inflammatory indications including
RMS, ulcerative colitis and Crohn’s disease.

About Multiple Sclerosis

Multiple sclerosis (MS) is a disease in which the immune system attacks
the protective myelin sheath that covers the nerves. The myelin damage
disrupts communication between the brain and the rest of the body.
Ultimately, the nerves themselves may deteriorate — a process that’s
currently irreversible. Signs and symptoms vary widely, depending on the
amount of damage and the nerves affected. Some people living with MS may
lose the ability to walk independently, while others experience long
periods of remission during which they develop no new symptoms. MS
affects approximately 400,000 people in the U.S. and approximately 2.5
million people worldwide.

RMS is characterized by clearly defined attacks of worsening neurologic
function. These attacks — often called relapses, flare-ups or
exacerbations — are followed by partial or complete recovery periods
(remissions), during which symptoms improve partially or completely with
no apparent progression of disease. RMS is the most common disease
course at the time of diagnosis. Approximately 85 percent of patients
are initially diagnosed with RMS, compared with 10-15 percent with
progressive forms of the disease.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next‐generation solutions in protein homeostasis, immuno‐oncology,
epigenetics, immunology and neuro‐inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Pinterest,
LinkedIn,
Facebook
and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the U.S. Securities and
Exchange Commission, including factors related to the proposed
transaction between Bristol-Myers Squibb and Celgene, such as, but not
limited to, the risks that: management’s time and attention is diverted
on transaction related issues; disruption from the transaction make it
more difficult to maintain business, contractual and operational
relationships; pending legal proceedings or any future litigation
instituted against Bristol-Myers Squibb, Celgene or the combined company
could delay or prevent the proposed transaction; and Bristol-Myers
Squibb, Celgene or the combined company is unable to retain key
personnel.

Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.

All trademarks are the property of their respective owners.

Contacts

Investors:
Nina Goworek
Executive Director, Investor Relations
908-673-9711

Media:
Catherine Cantone
Senior Director, Corporate
Communications
908-897-4256

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.